Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A Operating Income

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A (FBIOP) currently reports a operating income of $-29M as of June 2026. That compares with $-100M in the prior-year period — up 72.1% year over year. Use the charts on this page to explore Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's operating income history and peer comparisons.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A's operating income increased from $-100M to $-29M — a 72.1% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A reported $-29M in operating income as of June 2026. That compares with $-100M in the prior-year period — up 72.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A, and consider following FBIOP for alerts when major investors trade the stock.

Fortress Biotech- 9.375% PRF PERPETUAL USD 25 - Ser A is classified in the Healthcare sector. On operating income, it currently shows $-29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FBIOP with unrelated industries.